Accession Number : AD1023943

Title :   Micellar Drug Delivery and Proteomics Analysis for Effective Treatment of Resistant Prostate Cancer

Descriptive Note : Technical Report,15 Sep 2014,14 Sep 2015

Corporate Author : University of Nebraska Medical Center Omaha United States

Personal Author(s) : Mahato,Ram I

Full Text :

Report Date : 01 Dec 2015

Pagination or Media Count : 127

Abstract : We found good synergy between XIAP inhibitor embelin and anti-androgen such as bicalutamide and its analog CBD-IV 17 in killing prostate cancer cells. Since antiandrogens and XIAP inhibitor were highly hydrophobic, they were solubilized in polymeric micelles prepared using our newly synthesized copolymer, polyethylene glycol-b-poly (carbonate-colactide)(PEG-b-p(CB-co-PLA). Following in vitro characterization in terms of particle size and drug loading, these formulations were tested in prostate tumor bearing mice. Sequential administration of bicalutamide followed by embelin was more potent in regressing prostate tumor growth in mouse xenografts compared to monotherapy. Micelles usually are not very stable and tend to disintegrate upon dilution in the blood stream.

Descriptors :   prostate cancer , inhibitors , cancer research , Copolymers , therapeutics , drug therapy , micelles

Subject Categories : Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE